In September 2024, we sent open letters to the leading insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, urging them to do more for affordable access to insulin and insulin pen devices for people living with diabetes in low- and middle-income countries. We received replies from each corporation and marked them up with our comments and concerns:
